Cytokine profiles in the joint depend on pathology, but are different between synovial fluid, cartilage tissue and cultured chondrocytes by Tsuchida, A.I. (Anika) et al.
Tsuchida et al. Arthritis Research & Therapy 2014, 16:441
http://arthritis-research.com/content/16/5/441RESEARCH ARTICLE Open AccessCytokine profiles in the joint depend on
pathology, but are different between synovial
fluid, cartilage tissue and cultured chondrocytes
Anika I Tsuchida1, Michiel Beekhuizen1, Marieke C ‘t Hart1, Timothy RDJ Radstake2, Wouter JA Dhert1,3,
Daniel BF Saris1,4, Gerjo JVM van Osch5,6 and Laura B Creemers1*Abstract
Introduction: This study aimed to evaluate whether profiles of several soluble mediators in synovial fluid and
cartilage tissue are pathology-dependent and how their production is related to in vitro tissue formation by
chondrocytes from diseased and healthy tissue.
Methods: Samples were obtained from donors without joint pathology (n = 39), with focal defects (n = 65) and
osteoarthritis (n = 61). A multiplex bead assay (Luminex) was performed measuring up to 21 cytokines: Interleukin
(IL)-1α, IL-1β, IL-1RA, IL-4, IL-6, IL-6Rα, IL-7, IL-8, IL-10, IL-13, tumor necrosis factor (TNF)α, Interferon (IFN)γ, oncostatin
M (OSM), leukemia inhibitory factor (LIF), adiponectin, leptin, monocyte chemotactic factor (MCP)1, RANTES, basic
fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), vascular growth factor (VEGF).
Results: In synovial fluid of patients with cartilage pathology, IL-6, IL-13, IFNγ and OSM levels were higher than in
donors without joint pathology (P ≤0.001). IL-13, IFNγ and OSM were also different between donors with cartilage
defects and OA (P <0.05). In cartilage tissue from debrided defects, VEGF was higher than in non-pathological or
osteoarthritic joints (P ≤0.001). IL-1α, IL-6, TNFα and OSM concentrations (in ng/ml) were markedly higher in
cartilage tissue than in synovial fluid (P <0.01). Culture of chondrocytes generally led to a massive induction of most
cytokines (P <0.001). Although the release of inflammatory cytokines was also here dependent on the pathological
condition (P <0.001) the actual profiles were different from tissue or synovial fluid and between non-expanded and
expanded chondrocytes. Cartilage formation was lower by healthy unexpanded chondrocytes than by osteoarthritic
or defect chondrocytes.
Conclusions: Several pro-inflammatory, pro-angiogenic and pro-repair cytokines were elevated in joints with
symptomatic cartilage defects and/or osteoarthritis, although different cytokines were elevated in synovial fluid
compared to tissue or cells. Hence a clear molecular profile was evident dependent on disease status of the joint,
which however changed in composition depending on the biological sample analysed. These alterations did not
affect in vitro tissue formation with these chondrocytes, as this was at least as effective or even better compared to
healthy chondrocytes.* Correspondence: l.b.creemers@umcutrecht.nl
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Soluble mediators, such as cytokines, chemokines, adipo-
kines and growth factors, are key regulators of cartilage
metabolism. Under homeostatic conditions the produc-
tion of these mediators is tightly regulated. In many joint
diseases, including osteoarthritis (OA) and joint trauma,
elevated levels of inflammatory cytokines are present [1]
but their pathophysiological role is not always well es-
tablished. In inflammatory diseases such as rheumatoid
arthritis, the synovial cells produce large quantities of in-
flammatory cytokines and degradative enzymes [2], which
reach the cartilage through the synovial fluid. Although
less outspoken, synovial inflammation is also present in
OA [3,4] and sometimes in joints with cartilage defects
[5], and the balance between anabolic and catabolic me-
diators has been suggested to be in favour of catabolic
factors leading to a net breakdown of cartilage. In
addition to their possible role in the pathophysiology of
joint disease, soluble mediators present in the joint may
also affect cartilage repair, both in OA and in cartilage
defect treatment [6,7].
These mediators are not only produced by the synovial
lining cells, but also by resident chondrocytes in re-
sponse to both biological and mechanical stimuli [1]. In
fact, in OA certain cytokines appeared to be predomin-
antly produced by cartilage rather than synovial tissue
[8]. Furthermore, some mediators were shown to bind to
extracellular matrix components, such as glycosamino-
glycans (GAGs), in cartilage [9]. Local concentrations in
the microenvironment of the chondrocyte might there-
fore differ from those in the synovial fluid. Evaluating
the presence of mediators in the cartilage tissue in
addition to the synovial fluid might provide more insight
into the possible mechanisms of cartilage regeneration
and degeneration.
In addition to the cytokines in synovial fluid and car-
tilage extracellular matrix, studying the cytokine profile
during in vitro cartilage formation may provide essential
clues as to which mediators are important for tissue
engineering of cartilage and to what extent cytokine pro-
duction by chondrocytes may affect the outcome of cartil-
age repair procedures. Few studies have directly compared
healthy chondrocytes with chondrocytes obtained from
cartilage defects and/or osteoarthritic chondrocytes in
terms of regenerative capacity [10] and a comprehensive
secretory profile is lacking. Characterising the mediators
produced by both healthy and diseased chondrocytes may
allow for more specific inhibition of mediators in order to
improve cartilage regeneration, especially by dedifferen-
tiated or diseased chondrocytes.
In this study we therefore compared the presence of
soluble mediators commonly suggested to play a role in
joint pathology in synovial fluid and cartilage tissue for
donors with healthy cartilage, patients with symptomaticcartilage defects and patients with end-stage OA. In
addition, the production of these and additional cyto-
kines by isolated chondrocytes during in vitro cartilage
formation was investigated using both expanded and
nonexpanded chondrocytes obtained from donors with
different joint pathology. Clustering was investigated by
principal component analysis to verify whether the roles
and pathways for these cytokines are likely to be similar
in the various all of these biological samples assayed.Methods
Synovial fluid and cartilage sample collection and cell
isolation
Collection of all patient material and all aspects of the study
protocol were performed according to the Medical Ethical
regulations of the University Medical Centre Utrecht and
according to the ‘good use of redundant tissue for clinical
research’ guideline constructed by the Dutch Federation of
Medical Research Societies on collection of redundant tis-
sue for research [11]. This study does not meet the de-
finition of human subject research or require informed
consent. Anonymous use of redundant tissue for research
purposes is part of the standard treatment agreement with
patients in our hospital [12].
Macroscopically healthy articular cartilage and synovial
fluid was obtained from donors within 24 hours post mor-
tem (see Table 1 for details). Defect cartilage and synovial
fluid was obtained from donors undergoing either micro-
fracture or autologous chondrocyte implantation for focal
grade III and grade IV cartilage defects. During those pro-
cedures, the cartilage defect is debrided to remove all car-
tilage remnants down to the subchondral bone and create
a stable cartilage rim. The debrided cartilage was used. Of
the 31 patients with symptomatic cartilage defects, one
had associated anterior cruciate ligament injury and a his-
tory of partial menisectomy, another three had received
previous partial menisectomies and one an anterior cru-
ciate ligament reconstruction. OA cartilage and synovial
fluid was obtained from donors undergoing total knee
arthroplasty. Synovial fluid was spun down at 300 × g to
remove debris, and stored at –80°C until use or analysis.
Cartilage samples were rinsed in phosphate-buffered sa-
line (PBS), and either snap frozen in liquid nitrogen and
stored at –80°C until later protein extraction or cut into
small pieces and enzymatically digested overnight at 37°C
in 0.15% collagenase type II (Worthington, Lakewood, NJ,
USA) in Dulbecco’s modified Eagle’s medium (Gibco, Life
Technologies, Bleiswijk, the Netherlands) with penicillin/
streptomycin (100 U/ml/100 μg/ml; Invitrogen, Life Tech-
nologies). After digestion, the cell suspension was filtered
through a 70 μm cell strainer (BD Biosciences, San Diego
CA, USA), and the chondrocytes were spun down by
10 minutes of centrifugation at 300 × g.
Table 1 Donor characteristics
Donor type Synovial fluid Tissue Nonexpanded chondrocytes Expanded chondrocytes
Healthy n = 20 n = 9a n = 8a n = 15
Age, average (range) 40 (25 to 47) 69 (54 to 81) 66 (54 to 75) 67 (54 to 81)
% male Unknown 80 50 60
Cartilage defect n = 31 n = 16 n = 10 n = 13
Age, average (range) 33 (20 to 48) 33 (16 to 45) 32 (18 to 44) 24 (19 to 36)
% male Unknown 47 70 85
Osteoarthritis n = 27 n = 27 n = 12 n = 13
Age, average (range) 70 (53 to 81) 67 (46 to 90) 69 (49 to 83) 70 (46 to 83)
% male Unknown 23 38 38
aOf four healthy donors, both tissue and nonexpanded chondrocytes were analysed; for all the other donors, either synovial fluid, tissue, nonexpanded or
expanded cells were analysed.
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The frozen cartilage samples (Table 1) were cut into 7 μm
sections with a cryomicrotome. The sections were col-
lected and carefully weighed. Approximately 100 mg cartil-
age tissue was collected per sample and lysed in 5 μl lysis
buffer per milligram of tissue with complete protease in-
hibitor (Complete Lysis M, #04719964001; Roche Diag-
nostics, Almere, the Netherlands). The samples were
cooled on ice and homogenised using 1.4 mm ceramic
beads (VWR, Amsterdam, the Netherlands) in a bead
beater. Subsequently, the samples were centrifuged at 4°C
for 4 minutes at 20,217 × g and supernatants collected.
Supernatants were then filtered by centrifuging through a
polypropylene tube containing a 0.22 μm nylon membrane
(Spin-X column; Corning, Amsterdam, the Netherlands)
prior to measurements of the cytokine levels.
Measurement of cytokine levels
To determine the cytokine levels in the synovial fluids and
tissue extracts of healthy, defect and OA donors and in the
conditioned media (day 7) of healthy, defect and OA chon-
drocytes during in vitro tissue formation, a multiplex bead-
assay (Luminex, Luminex Corporation, Austin TX, USA)
was performed as described previously [13,14]. A panel of
a total 21 cytokines was available – interleukin (IL)-1α, IL-
1β, IL-1RA, IL-4, IL-6, IL-6Rα, IL-7, IL-8, IL-10, IL-13,
tumour necrosis factor alpha (TNFα), interferon gamma
(IFNγ), oncostatin M (OSM), leukaemia inhibitory factor
(LIF), adiponectin, leptin, monocyte chemotactic factor 1
(MCP1), RANTES, basic fibroblast growth factor (bFGF),
hepatocyte growth factor (HGF), and vascular endothelial
growth factor (VEGF) – of which 11 were measured in
the synovial fluid, 19 in tissue extracts and all 21 in condi-
tioned media. Briefly, specific antibodies were coupled to
carboxylated beads (Luminex Corporation, Austin, TX,
USA). The levels of IL-6 present in the synovial fluid have
been published previously [15]. Recombinant cytokines
were used to make a standard curve. Synovial fluid was
first treated with hyaluronidase (type IV-S; Sigma-Aldrich,Zwijndrecht, the Netherlands) at a concentration of 20 U/
ml for 30 minutes at 37°C and then filtered by centrifuging
through a Spin-X column. Subsequently, the synovial fluid
samples were diluted 1:2 with HPE-0.1375% Tween (San-
quin, Amsterdam, the Netherlands). To block possible
interfering antibodies present in the synovial fluid, the
samples were diluted with an equal volume of 10% (v/v)
normal rat and mouse serum (Rockland Immunochemi-
cals Inc., Gilbertsville, PA, USA). Tissue extracts and
medium samples were directly incubated with the coupled
beads. After incubation with the appropriate biotinylated
antibodies, samples were thoroughly washed and incu-
bated with streptavidin–phycoerythrin (BD Biosciences)
for 10 minutes. After washing, the samples were measured
and analysed using the Bio-Plex suspension system (Bio-
Rad Laboratories, Hercules, CA, USA) with Bio-Plex
Manager software, version 3.0. The concentration of cyto-
kines was expressed as picograms per microlitre using the
standard curves. Results of specific enzyme-linked im-
munosorbent assays for determination of cytokine levels
have previously been shown to be comparable with the
multiplex bead assay (Luminex) [8].
Chondrocyte-mediated tissue production in vitro
Isolated chondrocytes from healthy, defect and OA car-
tilage were used either directly after isolation or after
expansion to passage 2 (see Table 1 for more details). Ex-
pansion was performed in monolayers at 37°C and 5%
carbon dioxide at a seeding density of 5,000 cells/cm2 in ex-
pansion medium consisting of Dulbecco’s modified Eagle’s
medium, 10% foetal bovine serum (Hyclone, Thermo Scien-
tific, Etten-Leur, the Netherlands), penicillin/streptomycin
(100 U/ml/100 μg/ml) and 10 ng/ml bFGF (R&D Systems,
Minneapolis, MN, USA). Unexpanded chondrocytes and
expanded chondrocytes were seeded on collagen type II-
coated (Chicken sternal cartilage, #C9301; Sigma-Aldrich)
Millicell filters (Millipore Co., Bedford, MA, USA), at 1.6 ×
106 cells/cm2 and redifferentiated during 28 days in redif-
ferentiation medium consisting of Dulbecco’s modified
Tsuchida et al. Arthritis Research & Therapy 2014, 16:441 Page 4 of 15
http://arthritis-research.com/content/16/5/441Eagle’s medium, 0.2 mM L-ascorbic acid-2-phosphate
(AsAp; Sigma-Aldrich), 2% human serum albumin
(Sanquin), penicillin/streptomycin (100 U/ml/100 μg/ml),
2% insulin–transferrin–selenium-X (Invitrogen) and 5 ng/
ml transforming growth factor beta 2 (R&D systems).
Glycosaminoglycan and DNA analysis
After culture, the formed tissue was digested overnight in a
papain buffer (250 μg/ml papain (Sigma-Aldrich) in 50 mM
ethylenediamine tetraacetic acid and 5 mM L-cysteine) at
56°C, followed by determination of the GAG content
using the dimethylmethylene blue assay [16]. The ratio of
absorption at 540 nm to that at 595 nm was used to calcu-
late the GAG content, using chondroitin sulphate (shark;
Sigma-Aldrich) as a standard. Supernatants were also col-
lected and analysed for GAGs released into the medium.
The DNA content was determined from the papain
digest using a Picogreen DNA assay (Invitrogen) in ac-
cordance with the manufacturer’s instructions.
Histological evaluation
Newly formed cartilage on filters was fixed in 4% buffered
formaldehyde, dehydrated in alcohol, rinsed in xylene and
infiltrated and embedded with paraffin. For histology,
5 μm sections were deparaffinised in xylene, rehydrated in
alcohol and stained with safranin-O (Merck, Darmstadt,
Germany) for GAG and counterstained with Weigert’s
haematoxylin (Klinipath, Duiven, the Netherlands) and
0.4% fast green (Merck) for nuclei and cytoplasm,
respectively.
The deposition of type II collagen was evaluated by im-
munohistochemistry. Antigen retrieval was performed by
1 mg/ml pronase (Sigma-Aldrich) for 30 minutes at 37°C
followed by hyaluronidase incubation for 30 minutes at
37°C. After antigen retrieval, the sections were blocked
using a PBS–bovine serum albumin 5% solution for 30 mi-
nutes followed by overnight incubation at 4°C with pri-
mary antibody against human type II collagen (II-II6B3
1/100 in 5% PBS/bovine serum albumin; Hybridomabank,
Ioway City, Iowa, USA). A biotinylated secondary anti-
mouse antibody was used (1/200 in 5% PBS/bovine
serum albumin; GE Healthcare, Pollards Wood, UK) for
1 hour at room temperature, followed by incubation with
streptavidin/peroxidase (1/500 in 5% PBS/bovine serum
albumin; Beckman Coulter, Brea, CA, USA) for 1 hour at
room temperature. Antibody binding was visualised using
3-diaminobenzidine (Sigma-Aldrich). All immunohisto-
chemical sections were counterstained using Mayer’s
haematoxylin.
Statistical analysis
All statistical analyses were performed using SPSS 18.0
(SPSS Inc., Chicago, IL, USA). Results are displayed as
mean ± standard deviation. Cytokine levels were notdistributed normally, therefore differences in cytokine
levels between healthy, cartilage defect and OA donors
were determined using the Kruskall–Wallis test with
post hoc Mann–Whitney U test. Differences in cytokine
levels between synovial fluid and tissue were determined
using the Mann–Whitney U test, and those between tis-
sue, unexpanded and expanded cells with the Kruskall–
Wallis test. Principal component analysis was performed
to reduce correlated cytokines to a smaller set of un-
correlated factors delineating subsets of cytokines. Only
cytokines with communalities >0.5 were included. Loa-
ding factors were maximised using Varimax rotation
with Kaiser normalisation. The number of clusters was
decided based on the scree plot and eigenvalues (>1.0).
Cytokines were categorised per cluster when their loa-
ding scores were >0.5. A test for Cronbach’s alpha was
performed on each cluster to verify consistency. Separate
principal component analysis of healthy, cartilage defect
and OA samples was not possible due to the limited
number of subjects per disease condition. Differences in
GAG and DNA content between healthy, cartilage defect
and OA donors were determined using analysis of va-
riance with post hoc t test, and differences between unex-
panded and expanded chondrocytes by t test. Multiple
linear regression analysis with backward elimination was
performed to identify cytokines that best predict cartilage
regeneration as measured by GAG/DNA.
Results
Elevated levels of IL-6, IL-13, IFNγ, OSM and VEGF in
donors with symptomatic focal cartilage defects
In total, 11 soluble mediators were measured in the syn-
ovial fluid of healthy donors, donors with symptomatic
cartilage defects and osteoarthritic donors. Four of them
were present at significantly different concentrations,
namely IL-6, IL-13, IFNγ and OSM (P ≤0.001; Table 2).
The concentrations of IL-6 and OSM were significantly
lower in synovial fluid of donors without known joint
pathology than in synovial fluid of patients with cartilage
defects or OA (in line with previous data [15]). The con-
centrations of IL-13 and IFNγ were highest in synovial
fluid of patients with a cartilage defect.
A total of 19 soluble mediators were measured in car-
tilage tissue extracts of healthy cartilage, cartilage deb-
rided from defects and osteoarthritic cartilage (Table 3).
Only VEGF concentrations were statistically significantly
different, with the highest concentrations in cartilage
debrided from defects and the lowest concentrations in
healthy cartilage and a significant difference between
OA and defect cartilage (P <0.001; Tables 2 and 3).
To be able to compare the levels in synovial fluid and
cartilage tissue, the wet weight of tissue was taken to rep-
resent to its volume according to an average of 1.05 g/ml
density for tissues devoid of inorganic constituents [17]
Table 2 Cytokines in the synovial fluid and cartilage tissue
Synovial fluid Cartilage
Cytokines
(per ml SF)
Healthy
(n = 20)
Defect
(n =31)
Osteoarthritis
(n = 27)
P value Cytokines
per g tissue
Healthy
(n = 9)
Defect
(n = 16)
Osteoarthritis
(n = 27)
P value
IL-1α (pg/ml) 16 ± 10 (100%) 14 ± 8 (100%) 15 ± 22 (89%) 0.085 IL-1α (pg/g) 5 ± 13 (22%) 366 ± 706 (25%) 183 ± 391 (26%) 0.470
IL-1β (pg/ml) 1 ± 2 (25%) 15 ± 18 (55%) 8 ± 16 (41%) 0.032 IL-1β (pg/g) 0 ± 0 (0%) 23 ± 63 (13%) 0 ± 1 (4%) 0.336
IL-4 (pg/ml) 0 ± 0 (0%) 2 ± 3 (32%) 1 ± 4 (15%) 0.026 IL-4 (pg/g) 0 ± 0 (0%) 1 ± 2 (13%) 0 ± 1 (7%) 0.261
IL-6a (pg/ml) 64 ± 120 (40%) 261 ± 385 (96%) 396 ± 508 (82%) <0.001* IL-6 (pg/g) 1064 ± 3193 (11%) 1473 ± 3162 (19%) 935 ± 2739 (19%) 0.752
IL-7 (pg/ml) 0 ± 0 (0%) 0 ± 0 (0%) 5 ± 28 (4%) 0.459
IL-8 (pg/ml) 25 ± 29 (75%) 27 ± 33 (59%) 52 ± 95 (85%) 0.352 IL-8, ng/g 12 ± 20 (67%) 10 ± 30 (31%) 15 ± 44 (48%) 0.442
IL-10 (pg/ml) 1 ± 6 (5%) 0 ± 0 (0%) 9 ± 35 (15%) 0.134 IL-10 (pg/g) 0 ± 0 (0%) 812 ± 2113 (13%) 578 ± 1650 (15%) 0.400
IL-13 (pg/ml) 1 ± 2 (5%) 38 ± 41 (64%) 18 ± 40 (33%) <0.001* IL-13 (pg/g) 0 ± 0 (0%) 799 ± 1641 (25%) 250 ± 648 (15%) 0.121
TNFα (pg/ml) 0 ± 0 (0%) 2 ± 8 (9%) 4 ± 20 (11%) 0.324 TNFα (pg/g) 522 ± 1084 (22%) 3069 ± 4453 (25%) 1733 ± 3212 (30%) 0.467
IFNγ (pg/ml) 47 ± 17 (100%) 68 ± 38 (100%) 51 ± 69 (93%) 0.001* IFNγ (pg/g) 0 ± 0 (0%) 226 ± 848 (13%) 0 ± 0 (0%) 0.101
OSM (pg/ml) 2 ± 7 (5%) 22 ± 46 (64%) 38 ± 121 (22%) 0.001* OSM (pg/g) 66 ± 108 (44%) 170 ± 241 (38%) 220 ± 424 (37%) 0.786
LIF (pg/g) 0 ± 0 (0%) 2797 ± 6515 (13%) 3529 ± 10164 (22%) 0.279
Adiponectin (μg/g) 12 ± 10 (100%) 57 ± 62 (88%) 19 ± 29 (100%) 0.002
Leptin (ng/g) 15 ± 29 (33%) 120 ± 169 (63%) 112 ± 136 (83%) 0.026
MCP1 (pg/g) 182 ± 423 (22%) 1336 ± 1711 (50%) 1249 ± 1250 (68%) 0.044
RANTES (pg/g) 0 ± 0 (0%) 1225 ± 2163 (31%) 510 ± 1121 (22%) 0.056
bFGF (ng/g) 129 ± 335 (44%) 439 ± 691 (69%) 615 ± 719 (74%) 0.055
HGF (pg/g) 3171 ± 6757 (56%) 5824 ± 5110 (69%) 2986 ± 3452 (74%) 0.113
VEGF (ng/g) 19 ± 11 (100%) 212 ± 149 (88%) 49 ± 28 (100%) <0.001*
IL-1RA (pg/g) 495 ± 1017 (22%) 1856 ± 3172 (25%) 2504 ± 10792 (33%) 0.573
The presence of cytokines was measured in synovial fluid (SF) and cartilage tissue extracts from healthy donors and donors with symptomatic cartilage defects and osteoarthritic donors. Results are represented as
mean ± standard deviation (% of samples in which the cytokine was present). Differences in cytokine levels between healthy, cartilage defect and OA donors were determined using the Kruskall–Wallis test (P values
shown in table) with post hoc Mann–Whitney U test: synovial fluid – IL-6: H vs. CD, P <0.001; H vs. OA, P = 0.001; IL-13: H vs. CD, P <0.001; H vs. OA, P = 0.018; CD vs. OA, P = 0.029; IFNγ: H vs. CD, P = 0.008; H vs. OA,
P = 0.05; CD vs. OA, P = 0.001; OSM: H vs. CD, P <0.001; CD vs. OA, P = 0.030; tissue – VEGF: H vs. CD, P <0.001; H vs. OA, P = 0.003; CD vs. OA, P <0.001. bFGF, basic fibroblast growth factor; CD, cartilage defect; H,
healthy; HGF, hepatocyte growth factor; IFNγ, interferon gamma; IL, interleukin; LIF, leukaemia inhibitory factor; MCP1, monocyte chemotactic factor 1; OA, osteoarthritis; OSM, oncostatin M; RANTES, regulated upon
activation normal T cell expressed and presumably secreted; TNFα, tumour necrosis factor alpha; VEGF, vascular endothelial growth factor. *P <0.001. aData published previously [15].
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Table 3 Cytokines produced by chondrocytes in native tissue and in culture per cell
Tissue Unexpanded chondrocytes Expanded chondrocytes
Cytokine
(per mg DNA)
Healthy
(n = 9)
Defect
(n = 16)
Osteoarthritis
(n = 27)
P value Healthy
(n = 8)
Defect
(n = 10)
Osteoarthritis
(n = 12)
P value Healthy
(n = 15)
Defect
(n = 13)
Osteoarthritis
(n = 13)
P value
IL-1α (pg/mg) 5 ± 12 198 ± 630 408 ± 1,062 0.844 439 ± 268 993 ± 743 460 ± 271 0.006 1,718 ± 2,689 1,978 ± 1,464 2,569 ± 2,528 0.006
IL-1β (pg/mg) 0 ± 0 14 ± 41 0 ± 2 0.336 14 ± 33 816 ± 968 125 ± 151 <0.001* 283 ± 368 369 ± 270 459 ± 408 0.010
IL-4 (pg/mg) 0 ± 0 0 ± 1 0 ± 1 0.536 18 ± 49 18 ± 40 40 ± 76 0.691 148 ± 224 200 ± 163 263 ± 259 0.002
IL-6 (pg/mg) 4,813 ± 14,438 678 ± 1,867 1,840 ± 6,389 0.928 1,715 ± 397 1,739 ± 437 1,918 ± 77 0.037 423 ± 414 136 ± 268 721 ± 319 <0.001*
IL-7 (pg/mg) 1,288 ± 378 1,120 ± 547 1,304 ± 619 0.457 300 ± 401 411 ± 343 545 ± 555 0.008
IL-8 (ng/mg) 39 ± 94 7 ± 23 28 ± 102 0.192 1,070 ± 572 786 ± 625 784 ± 399 0.036 28 ± 36 36 ± 43 113 ± 85 <0.00*
IL-10 (pg/mg) 0 ± 0 252 ± 783 969 ± 3,344 0.483 3,021 ± 2,455 16,529 ± 20,669 4,925 ± 3,429 0.015 5,200 ± 6,788 6,524 ± 4,806 9,471 ± 9,333 0.029
IL-13 (ng/mg) 0 ± 0 378 ± 783 545 ± 1,531 0.296 2,027 ± 597 3,249 ± 1,155 2,936 ± 1,220 0.002 4,486 ± 6,088 5,614 ± 3,730 6,787 ± 5,935 0.006
TNFα (pg/mg) 499 ± 1,020 2,054 ± 4,520 3,567 ± 8,065 0.714 253 ± 184 414 ± 346 426 ± 452 0.319 183 ± 221 217 ± 148 310 ± 315 0.154
IFNγ (pg/mg) 0 ± 0 175 ± 677 0 ± 0 0.101 50 ± 214 54 ± 245 173 ± 636 0.615 538 ± 866 720 ± 767 1,036 ± 1,287 0.079
OSM (pg/mg) 156 ± 279 135 ± 239 394 ± 776 0.963 111 ± 164 2,736 ± 3,990 369 ± 640 0.138 26 ± 37 26 ± 23 46 ± 55 0.135
LIF (ng/mg) 0 ± 0 1 ± 4 5 ± 13 0.238 76 ± 50 194 ± 127 97 ± 56 0.005 38 ± 37 23 ± 16 48 ± 24 0.000*
Adiponectin (ng/mg) 15,700 ± 12,550 60,900 ± 74,720 20,000 ± 26,960 0.238 1,582 ± 903 3,689 ± 5,136 1,777 ± 1,220 0.723 20 ± 31 22 ± 21 36 ± 41 0.022
Leptin (ng/mg) 14 ± 29 75 ± 151 161 ± 199 0.009 22 ± 7 26 ± 7 22 ± 9 0.125 22 ± 24 29 ± 18 35 ± 27 0.014
MCP1 (pg/mg) 672 ± 1,890 806 ± 1,067 2,216 ± 3,780 0.068 376 ± 148 626 ± 474 331 ± 219 0.065 43 ± 14 38 ± 20 53 ± 49 0.176
RANTES (pg/mg) 0 ± 0 986 ± 2,687 1,074 ± 2,852 0.208 129 ± 149 63 ± 80 106 ± 89 0.057 3 ± 4 1 ± 1 4 ± 4 0.034
bFGF (ng/mg) 196 ± 527 514 ± 762 760 ± 923 0.089 12 ± 15 39 ± 68 11 ± 18 0.427 20 ± 17 23 ± 14 34 ± 26 0.021
HGF (pg/mg) 3,262 ± 6,163 5763 ± 10,551 3,911 ± 4,661 0.565 151 ± 243 431 ± 470 353 ± 534 0.118 4,243 ± 6,533 5,314 ± 4,061 7,242 ± 7,595 0.004
VEGF (ng/mg) 33 ± 22 173 ± 133 66 ± 53 <0.001* 638 ± 468 828 ± 522 742 ± 298 0.333 126 ± 23 133 ± 29 124 ± 25 0.610
IL-1RA (pg/mg) 475 ± 960 990 ± 1938 1,871 ± 7,209 0.868 2,611 ± 2,167 20,259 ± 2,3520 11,005 ± 17,284 0.002 349 ± 260 433 ± 260 579 ± 442 0.031
IL-6Rα (pg/mg) 8,217 ± 2,190 5,397 ± 5,195 4,666 ± 5,094 0.037 3,276 ± 10,387 593 ± 324 456 ± 333 0.064
To compare the production of cytokines by chondrocytes in their native tissue (tissue extracts) and during culture (conditioned media day 7, both nonexpanded and expanded chondrocytes), cytokine production was
evaluated per DNA in samples from healthy cartilage, debrided cartilage from defects and osteoarthritic cartilage. Results are represented as mean ± standard deviation. Differences in cytokine levels between healthy,
cartilage defect and OA donors were determined using the Kruskall–Wallis test (P values shown in table) with post hoc Mann–Whitney U test: tissue – VEGF: H vs. CD, P = 0.002; H vs. OA, P = 0.024; CD vs. OA,
P = 0.002; unexpanded chondrocytes – IL-1β: H vs. CD, P <0.001; H vs. OA, P = 0.002; CD vs. OA, P = 0.013; expanded chondrocytes – IL-6: H vs. CD, P <0.001; H vs. OA, P <0.001; CD vs. OA, P <0.001; IL-8: H vs. OA,
P <0.001; CD vs. OA, P <0.001; H vs. OA, P = 0.008; CD vs. OA, P <0.001. bFGF, basic fibroblast growth factor; CD, cartilage defect; H, healthy; HGF, hepatocyte growth factor; IFNγ, interferon gamma; IL, interleukin;
LIF, leukaemia inhibitory factor; MCP1, monocyte chemotactic factor 1; OA, osteoarthritis; OSM, oncostatin M; RANTES, regulated upon activation normal T cell expressed and presumably secreted; TNFα, tumour
necrosis factor alpha; VEGF, vascular endothelial growth factor. *P <0.001.
Tsuchida
et
al.A
rthritis
Research
&
Therapy
2014,16:441
Page
6
of
15
http://arthritis-research.com
/content/16/5/441
Tsuchida et al. Arthritis Research & Therapy 2014, 16:441 Page 7 of 15
http://arthritis-research.com/content/16/5/441such as bone (Table 2). This would underestimate values
by 5% when expressed per volume unit. Concentrations of
IL-1α, IL-1β, IL-6, TNFα, IFNγ and OSM were different
between synovial fluid and cartilage tissue (P <0.01), re-
gardless of whether the tissue was diseased or not. How-
ever, especially in 1 ml cartilage debrided from defects
and OA cartilage, some tissue explants revealed concen-
trations of IL-1α, IL-6, TNFα and OSM that were at least
10-fold to 100-fold higher than in 1 ml synovial fluid
(Table 2).
Cytokine production by isolated and cultured
chondrocytes during in vitro tissue formation
When comparing cytokine presence per milligram of
DNA in native tissue with the levels produced during
in vitro tissue formation, cytokine production by chon-
drocytes in cell culture was generally much higher than
the levels found in their native matrix (P <0.001 for all
cytokines, except OSM P = 0.043; Table 3). There were
no differences in DNA content between healthy, car-
tilage defect and OA tissue (P = 0.1) (Table 3). Excep-
tions were TNFα, adiponectin, bFGF and HGF, which
were lower (P <0.001 for all cytokines) in cultured cells,
and leptin, which was similar. IL-1β, IL-4, IL-10, IL-13,
IFNγ, LIF and RANTES were not present in healthy car-
tilage tissue, but were induced during in vitro tissue
formation.
Soluble mediator production by isolated but unex-
panded chondrocytes during in vitro cartilage formation
was very similar between healthy, cartilage defect and
OA chondrocytes (Table 3). Only IL-1β was produced at
significantly higher amounts by chondrocytes from deb-
rided cartilage from defects compared with healthy and
OA chondrocytes (P <0.001; Table 3).
Expansion in monolayers for two passages had a major
effect on cytokine secretion. The secretion of most cyto-
kines was reduced at least by one-half after expansion, but
the expression of IL4, IFNγ, HGF and, to a lesser degree,
IL-1α and IL-1β was clearly increased by expansion of
chondrocytes (Table 3). Although before expansion only
IL-1β was differentially released between chondrocytes
from different joint pathologies, culture-expanded chon-
drocytes from OA cartilage showed a higher production
of IL-6, IL-8 and LIF during regeneration culture com-
pared with chondrocytes from healthy cartilage and/or
cartilage debrided from defects (P <0.001; Table 3).
Cartilage matrix formation during culture
Total GAG production per DNA was not different bet-
ween healthy, cartilage defect and OA nonexpanded
chondrocytes (Figure 1C). However, most of the GAG
produced during culture was not retained in the newly
formed tissue but released in the medium (Figure 1B). Re-
markably, unexpanded chondrocytes from defect cartilage(GAG/DNA, 19.6 ± 15.1 μg/μg) and OA chondrocytes
(GAG/DNA, 22.8 ± 17.1 μg/μg) retained more of the
produced GAG in the matrix than isolated unexpanded
chondrocytes from healthy cartilage (GAG/DNA, 9.4 ±
4.4 μg/μg; P <0.001) (Figure 1A). However, we did not
see this same difference in safranin-O staining intensity
(Figure 2). Nonquantitative evaluation of collagen II de-
position showed clear collagen II staining without ap-
parent differences between donor types (Figure 3).
The GAG content per DNA of the newly formed cartil-
age by culture-expanded chondrocytes after 4 weeks of
culture was lower than that by unexpanded chondrocytes
and not different between chondrocytes isolated from
healthy cartilage, cartilage defect or OA. In contrast, total
GAG production per DNA was highest by expanded
chondrocytes from cartilage debrided from defects
(Figure 1C), which was associated with a higher GAG
release by these cells (Figure 1B). The newly formed
cartilage matrix by expanded cells contained collagen
type II without apparent differences between donor types
(Figure 3).
Cluster analysis
Principal component analysis on cytokine levels of syn-
ovial fluid, cartilage and in vitro produced tissue was per-
formed to identify the existence of specific subsets of
cytokines, indicating involvement in different biological
processes. Clustering of specific cytokines was indeed very
different between cartilage tissue and nonexpanded cells.
In order to facilitate comparison of clusters between tissue
and cells we chose to colour all cytokines belonging to the
same cluster a certain colour (see Figure 4). Clustering in
expanded cells was possibly even more distinct because
here two-thirds of the variance could be explained by a
large cluster of many cytokines (Figure 4).
Synovial fluid
Principal component analysis of synovial fluid revealed
three clusters of correlated cytokines (Table 4). Cluster 1
consisted of IL-1α, IL-7, IL-8, IL-10, TNFα and OSM,
and explained 53% of variance with an eigenvalue of 5.9.
Cluster 2 contained IL-1β, IL-4 and IL-13 (variance
explained 27%, eigenvalue 2.9), and cluster 3 contained
IL-6 and IFNγ (variance explained 10%, eigenvalue 1.1).
Cartilage tissue
A total of five clusters were identified that respectively
explained 33%, 14%, 11%, 11% and 7% of variance
(eigenvalues 6.2, 2.7, 2.1, 2.0 and 1.3 respectively;
Table 5). Although some of the cytokines found in clus-
ter 1 (IL-1α, IL-10, IL-13, TNFα, OSM, LIF, MCP1,
RANTES) showed some overlap with cluster 1 identified
in synovial fluid, mostly clusters were different. Compo-
nents of cluster 2 were adiponectin, bFGF, HGF and
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Figure 1 Cartilage matrix production by healthy, cartilage defect and osteoarthritis chondrocytes. Cartilage regeneration cultures of
three healthy (H), three cartilage defect (CD) and three osteoarthritic (OA) donors, with either nonexpanded or expanded chondrocytes.
(A) Glycosaminoglycan (GAG) content per DNA, (B) cumulative GAG release per DNA, and (C) total GAG production (GAG content + cumulative
GAG release) per DNA after 28 days of culture. *P <0.05, †P <0.05 compared with CD and OA; ‡P <0.05 compared with H and OA.
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http://arthritis-research.com/content/16/5/441VEGF; those of cluster 3 were IL-1β and IFNγ; those of
cluster 4 were IL-6 and IL-8; and components of cluster
5 were IL-4, leptin and IL-1RA.In vitro tissue formation
Principal component analysis of the cytokines produced by
nonexpanded cells revealed five clusters that respectively
Figure 2 Safranin O staining of newly formed tissue by healthy, cartilage defect and osteoarthritis chondrocytes. Safranin O staining of
newly formed tissue after redifferentiation of chondrocytes on type II collagen-coated filters after 28 days of culture. (A) Nonexpanded healthy
chondrocytes, (B) nonexpanded cartilage defect chondrocytes, (C) nonexpanded osteoarthritic chondrocytes, (D) expanded healthy chondrocytes,
(E) expanded cartilage defect chondrocytes, and (F) expanded osteoarthritic chondrocytes.
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http://arthritis-research.com/content/16/5/441explained 34%, 19%, 12%, 8% and 5% of variance
(eigenvalues 7.1, 3.9, 2.5, 1.6 and 1.1 respectively; Table 6).
Cluster 1 contained IL-1α, IL-1β, IL-10, OSM, MCP1 and
IL-1RA; cluster 2 contained IL-4, IL-7, IL-13, IFNγ, leptin
and HGF; cluster 3 contained IL-6, IL-8 and RANTES;
cluster 4 contained adiponectin, bFGF and TNFα; and
cluster 5 contained LIF, VEGF and IL-6Rα. Cytokines pro-
duced by expanded cells clustered in only four clusters
(66%, 11%, 6% and 5% of variance explained with eigen-
values of 13.8, 2.4, 1.2 and 1.0 respectively; Table 7). Clus-
ter 1 consisted of IL-1α, IL-1β, IL-1RA, IL-4, IL-7, IL-10,
IL-13, TNFα, IFNγ, OSM, adiponectin, leptin, bFGF and
HGF, and explained most of the variance; cluster 2 of IL-6,
IL-8, LIF, MCP1 and RANTES; cluster 3 of VEGF; andFigure 3 Collagen type II in newly formed tissue by healthy, cartilage
immunohistochemistry of newly formed tissue after redifferentiation of chond
(A) Nonexpanded healthy chondrocytes, (B) nonexpanded cartilage defect ch
healthy chondrocytes, (E) expanded cartilage defect chondrocytes, and (F) excluster 4 consisted of IL-6Rα. None of the cytokines or
clusters was related to GAG/DNA production.
Discussion
To the best of our knowledge, this is the first report di-
rectly comparing cytokine presence in synovial fluid and
in cartilage and cytokine production by isolated chon-
drocytes from donors without joint pathology, patients
with symptomatic cartilage defects and patients with
OA. Several proinflammatory, proangiogenic and pro-
repair cytokines were elevated in donors with symp-
tomatic cartilage defects and OA. Especially in diseased
joints, local concentrations of inflammatory cytokines
present in the cartilage tissue were markedly higher thandefect and osteoarthritis chondrocytes. Collagen type II
rocytes on type II collagen-coated filters after 28 days of culture.
ondrocytes, (C) nonexpanded osteoarthritic chondrocytes, (D) expanded
panded osteoarthritic chondrocytes.
Cartilage
  tissue 
Non-expanded 
 chondrocytes 
  Expanded 
chondrocytes
IL-1
IL-1
IL-4
IL-6
IL-7
IL-8
IL-10
IL-13
TNF
IFN
OSM
LIF
Adiponectin
Leptin
MCP1
RANTES
bFGF
HGF
VEGF
IL-1RA
IL-6R
Cluster explaining most of the variance
Cluster explaining second to most of the variance
Cluster explaining third to most of the variance
Cluster explaining fourth to most of the variance
Cluster explaining fifth to most of the variance
Not measured
Figure 4 Principle component analyses of cytokines in cartilage tissue and cells. Principal component analysis of the measured cytokines in
cartilage tissue and conditioned media (day 7) of nonexpanded and expanded chondrocytes during regeneration. Different clusters are indicated
by different colours. bFGF, basic fibroblast growth factor; HGF, hepatocyte growth factor; IFNγ, interferon gamma; IL, interleukin; LIF, leukaemia
inhibitory factor; MCP1, monocyte chemotactic factor 1; OSM, oncostatin M; RANTES, regulated upon activation normal T cell expressed and
presumably secreted; TNFα, tumour necrosis factor alpha; VEGF, vascular endothelial growth factor.
Table 4 Principal component analysis of synovial fluid
Mediator Cluster
1 2 3
IL-7 0.997
IL-10 0.966
TNFα 0.938
IL-8 0.874
OSM 0.747
IL-1α 0.661
IL-1β 0.970
IL-13 0.956
IL-4 0.919
IL-6 0.876
IFNγ 0.745
Eigenvalues 5.9 2.9 1.1
Variance explained (%) 53 27 10
Cronbach’s alpha 0.829 0.680 0.228
IFNγ, interferon gamma; IL, interleukin; OSM, oncostatin M; TNFα, tumour
necrosis factor alpha.
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greatly increased during in vitro tissue production by
isolated chondrocytes. Interestingly, different cytokines
were regulated by the underlying pathology status in
synovial fluid, cartilage tissue and isolated chondrocytes.
This was further supported by clustering of correlated
cytokines, which was different between synovial fluid,
cartilage tissue and cultured cells, indicating that the
cytokines were involved in different biological processes
depending on the biological sample analysed.
We observed high concentrations of inflammatory
(IFNγ, OSM, IL-6) and pro-repair (IL-13) cytokines in
synovial fluid of joints with cartilage defects and OA.
The increased presence of these cytokines may be one of
the reasons for the inferior clinical results observed for
autologous chondrocyte implantation in patients with
longer existing degenerative defects and OA [18,19]. Ele-
vated levels of inflammatory mediators have previously
been demonstrated in the synovial fluid of patients with
joint trauma and OA [20], and synovial fluids from these
patients have been shown to hamper cartilage regene-
ration [6,21]. However, the composition of the synovial
Table 5 Principal component analysis of cartilage tissue
Mediator Cluster
1 2 3 4 5
IL-1α 0.947
TNFα 0.926
OSM 0.914
RANTES 0.912
IL-10 0.835
IL-13 0.814
MCP1 0.745
LIF 0.693
Adiponectin 0.846
HGF 0.789
bFGF 0.664
VEGF 0.610
IL-1β 0.963
IFNγ 0.933
IL-6 0.967
IL-8 0.945
IL-4 0.690
Leptin 0.508
IL-1RA −0.466
Eigenvalues 6.2 2.7 2.1 2.0 1.3
Variance explained (%) 33 14 11 11 7
Cronbach’s alpha 0.772 0.024 0.196 0.272 0.001
bFGF, basic fibroblast growth factor; HGF, hepatocyte growth factor; IFNγ,
interferon gamma; IL, interleukin; LIF, leukaemia inhibitory factor; MCP1,
monocyte chemotactic factor 1; OSM, oncostatin M; RANTES, regulated upon
activation normal T cell expressed and presumably secreted; TNFα, tumour
necrosis factor alpha; VEGF, vascular endothelial growth factor.
Table 6 Principal component analysis of nonexpanded
chondrocytes
Mediator Cluster
1 2 3 4 5
OSM 0.954
IL-10 0.932
IL-1β 0.889
MCP1 0.859
IL-1α 0.804
IL-1RA 0.700
Leptin 0.880
HGF 0.857
IL-13 0.817
IL-4 0.772
IL-7 0.754
IFNγ 0.661
IL-8 −0.856
IL-6 0.808
RANTES 0.682
bFGF 0.764
Adiponectin 0.750
TNFα 0.667
VEGF 0.741
LIF 0.619
IL-6R 0.588
Eigenvalues 7.1 3.9 2.5 1.6 1.1
Variance explained (%) 34 19 12 8 5
Cronbach’s alpha 0.152 0.392 −3.235 0.032 0.068
bFGF, basic fibroblast growth factor; HGF, hepatocyte growth factor; IFNγ,
interferon gamma; IL, interleukin; LIF, leukaemia inhibitory factor; MCP1,
monocyte chemotactic factor 1; OSM, oncostatin M; RANTES, regulated upon
activation normal T cell expressed and presumably secreted; TNFα, tumour
necrosis factor alpha; VEGF, vascular endothelial growth factor.
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http://arthritis-research.com/content/16/5/441fluid in patients with symptomatic cartilage defects had
hardly been characterised until now. In joint trauma,
levels of inflammatory cytokines have been shown to be
very high initially and decrease over the course of weeks
[22]. Likewise, we found higher levels of IL-13 and IFNγ
in the synovial fluids of cartilage defect donors than in
OA donors. A recent study by Heard and colleagues [23]
also evaluated the presence of cytokines in synovial fluid
of patients with severe and mild OA. Mild OA was de-
fined as cartilage damage <2 Outerbridge score on arth-
roscopy (which means the cartilage damage was partial
thickness at most), which is milder than the patients
with cartilage defects included in this study that were
mostly full thickness cartilage defects. They reported on
a similar increase in IL-6 with increasing cartilage da-
mage. However, contrary to our results they did not find
higher levels of IFNγ and IL-13, possibly because car-
tilage damage in their mild OA groups was less severe
than in our cartilage defects group. Interestingly, they
were also able to use principal component analysis toidentify two main components by which they could
make a distinction between healthy and OA patients.
Unfortunately, due to the limited sample size we were
not able to do the same.
Generally, inflammatory mediators are thought to
negatively affect cartilage integrity, but this may be too
simplistic a view. OSM present in the synovial fluid is in-
deed known to inhibit in vitro cartilage regeneration
[21]. However, IFNγ can also inhibit IL-1-induced matrix
metalloproteinase-13 expression in healthy and osteo-
arthritic chondrocytes [24,25], and we have recently
shown that IL-6 can also stimulate cartilage matrix for-
mation under specific conditions [15]. Effects of cyto-
kines may therefore not only depend on the presence of
other cytokines with opposite effects, but also on the
disease status, and effects on chondrocytes may be dif-
ferent than on other cell types. The elevated presence of
Table 7 Principal component analysis of expanded
chondrocytes
Mediator Cluster
1 2 3 4
IL-4 0.980
IL-1β 0.976
Adiponectin 0.971
Leptin 0.963
TNFα 0.958
IL-1α 0.954
IL-7 0.954
IL-10 0.953
HGF 0.944
IFNγ 0.942
IL-13 0.940
IL-1RA 0.926
OSM 0.912
bFGF 0.845
IL-8 0.817
IL-6 0.788
RANTES 0.671
LIF 0.635
MCP1 0.541
VEGF 0.847
IL-6R 0.914
Eigenvalues 13.8 2.4 1.2 1.0
Variance explained (%) 66 11 6 5
Cronbach’s alpha 0.812 0.293 n.a. n.a.
bFGF, basic fibroblast growth factor; HGF, hepatocyte growth factor; IFNγ,
interferon gamma; IL, interleukin; LIF, leukaemia inhibitory factor; MCP1,
monocyte chemotactic factor 1; n.a., not available; OSM, oncostatin M;
RANTES, regulated upon activation normal T cell expressed and presumably
secreted; TNFα, tumour necrosis factor alpha; VEGF, vascular endothelial
growth factor.
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now. IL-13 is a T-helper 2 cytokine that mediates alter-
native macrophage activation, a process that is now
recognised to play a role not only in immunity, but also
in tissue homeostasis and repair [26]. IL-13 is classically
T-helper 2 derived, but it can also be produced by va-
rious other cells and mediates fibrotic aspects of innate
immune activation through both transforming growth
factor beta-dependent and transforming growth factor
beta-independent pathways in pulmonary, hepatic, renal,
dermal and gastrointestinal inflammation and fibrosis
[27]. The direct effects of IL-13 on chondrocytes are not
well known, but it has been shown to prevent collagen
release induced by IL-1α and OSM in bovine nasal car-
tilage [28]. The effects on inflammation and cartilage in-
tegrity have been evaluated in various murine arthritismodels, but not in OA models or defect models. De-
creased cartilage destruction and chondrocyte apoptosis
were found with local overexpression of IL-13, but both
decreased inflammation [29] and increased inflammation
[30] were reported depending on the model employed.
Furthermore, microarray analysis of peripheral blood
cells of patients with early OA (limited damage to the
cartilage surface at arthroscopy, traumatic chondral de-
fects excluded) identified IL-13 receptor as one of the
six genes significantly downregulated [31]. It may be in-
teresting to explore whether IL-13 receptor downregula-
tion also occurs in patients with focal cartilage defects
and whether this is predictive for outcome.
We also observed that the concentrations of the in-
flammatory cytokines IL-1α, IL-1β, IL-6, TNFα, IFNγ
and OSM in diseased cartilage tissue were distinctly ele-
vated compared with those found in synovial fluid. This
may indicate that their role in cartilage turnover in these
conditions may be more substantial than can be deduced
from only evaluating synovial fluid concentrations. All of
these cytokines can have catabolic effects on cartilage
and chondrocytes [32]. This also indicates that although
the synovial membrane has been commonly implied in
governing the inflammatory process leading to cartilage
destruction, it appears that other tissues, including the
cartilage itself, may guide this. The origin of these cyto-
kines, however, is unclear. While IFNγ and IL-1β indeed
were found to be actively produced by OA cartilage in
in vitro explant cultures [8], IL-6 and OSM have been
found to be produced by OA synovial lining but not by
cartilage. Other tissues in the joint, such as the under-
lying bone, may therefore also have produced some of
the factors we measured in native cartilage tissue.
In cartilage tissue an increased presence of VEGF was
found in cartilage debrided from defects and to a lesser
extent also in OA cartilage compared with healthy car-
tilage. We did not evaluate the presence of VEGF in
synovial fluid, but in a recent study in end-stage OA pa-
tients undergoing knee arthroplasty [20], in which the
levels of IL-6, TNFα and VEGF were measured, almost
identical levels of IL-6 and TNFα as in the current study
and also high levels of VEGF were present. Additional to
its stimulatory effects on angiogenesis, VEGF may dir-
ectly influence cartilage. Increased presence of VEGF
and its receptors have been previously found in OA
cartilage tissue [33]. VEGF has been implicated in OA
pathogenesis since injection of VEGF into mice knees
induced OA [34] and VEGF immunolocalisation corre-
lated with cartilage destruction in several experimental
animal models [35]. More recently it has not only been
detected in late OA but also in early stages of OA [36].
VEGF has also been implicated to play a role in regener-
ation because it was shown to inhibit aggrecan and col-
lagen II synthesis [37] and inhibition of VEGF using a
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[38]. Our results also support a role for VEGF in cartil-
age defects, although small quantities were also found in
healthy tissue.
Expansion is known to lead to a loss of chondrocyte
phenotype [39]. Therefore it may not be surprising that
also the production of cytokines changes with expansion.
However, culturing chondrocytes generally led to a mas-
sive induction of cytokines released, which has not been
shown before. The role of this generalised upregulation
of cytokine production in cell culture is not clear, nor
what mechanism is involved. In cartilage, like in general
wound healing, a temporary inflammatory activation has
been suggested to be crucial for chondrogenic differenti-
ation [40]. However, despite this general upregulation,
differences between healthy and diseased chondrocytes
remained. Nonexpanded chondrocytes obtained from
debrided defect cartilage produced more IL-1β than
healthy and OA chondrocytes, and IL-6, IL-8 and LIF
were differentially produced by expanded chondrocytes.
IL-6 and IL-8 are two key cytokines known to be secreted
by senescent cells, something known as the senescence-
associated secretory phenotype [41,42]. Both replication as
well as stresses such as oxidative stress, DNA damage re-
agents and several cytokines, including IL-6 and IL-8
[41,42], can induce DNA damage and telomere shor-
tening. A stress-induced rather than replication-induced
senescence-like phenotype has been reported in OA chon-
drocytes, especially near osteoarthritic lesions [43,44].
Expansion of the OA chondrocytes may have amplified
the already present DNA damage, thereby increasing the
senescence-associated secretion of cytokines. Differences
in age between donors with cartilage defects and those
with OA in particular may also have contributed to dif-
ferences in cytokine levels [45].
Chondrocyte cell cultures are frequently used to study
inflammatory mechanisms involved in cartilage meta-
bolism and OA [46,47]. However, cytokine profiling as
well as clustering of correlated cytokines were distinctly
different between native tissue and cartilage cells in cul-
ture, even when the cells were not expanded in culture
and had a differentiated chondrogenic phenotype. Cor-
related cytokines identified by principal component ana-
lysis are thought to indicate an underlying biological
process. The large difference in clustering between car-
tilage tissue and chondrocyte culture indicates that re-
sults obtained from studying the effects of cytokines on
cartilage explants probably cannot be extrapolated to tis-
sue regeneration cultures. Likewise, cytokines reported
to have negative effects on cartilage integrity in OA may
not necessarily also be detrimental to cartilage repair
in autologous chondrocyte implantation. The different
clustering of cytokines released by chondrocytes in cul-
ture compared with in native tissue may further indicatea general response to culture. In this regard, the loss of
diversity with the expansion of chondrocytes (the first
cluster explained more than three-quarters of the va-
riance in expanded cells) further calls for caution with
extrapolation of the results of chondrocyte culture to
clinical OA, even if the cells are redifferentiated as in
our culture model.
Despite the increased release of inflammatory cytokines
by chondrocytes obtained from cartilage debrided from
defects and OA cartilage, in vitro cartilaginous tissue for-
mation with these chondrocytes was at least as good as or
even superior to regeneration with healthy chondrocytes
in terms of GAG production, confirming other studies
[48-51]. In fact, GAG production is increased in mild to
moderate severity OA cartilage [52,53].
Regression analysis did not reveal any cytokines or
clusters of cytokines that correlated with cartilage matrix
production. Cytokines could have dual or opposing ef-
fects. Perhaps other, here unmeasured, mediators are im-
portant for regeneration, or cytokine release during cell
culture reflects a more general response to culture ra-
ther than a pathophysiological process. Unfortunately we
did not measure all of these cytokines produced during
regeneration in synovial fluid as we started out by meas-
uring cytokines in synovial fluid that were previously
found in pathological joints and were suggested to play a
role in cartilage degeneration. Not much was known on
chondrocyte-based production, so we measured a much
broader panel of cytokines here. We agree that in re-
trospect it would have been interesting to see whether
cytokines differentially regulated in chondrocytes could
be traced back to synovial fluid, but unfortunately the
amount of synovial fluid specimens especially from
healthy joints is very limited and therefore we cannot
perform more measurements.
Further research is needed to clarify the role, if any, of
cytokines during regeneration.
Limitations of our study include the fact that donors
were not age or gender matched. We therefore cannot
exclude that at least part of the observed higher con-
centration of inflammatory markers was age associated.
However, patients with symptomatic cartilage defects are
young and predominantly male [54] whilst OA generally
affects older patients, so these differences between the
populations are inherent to the affliction. Secondly, we
mostly saw higher inflammation in patients with cartilage
defects; therefore, if anything, eliminating age-associated
inflammation will probably result in even larger dif-
ferences. Further, the collection of tissue from donors
without joint pathology was performed post mortem as
opposed to the intraoperative collection of OA and car-
tilage defect synovial fluid. Synovial fluid collection was
performed by needle aspiration and not lavage, thereby
eliminating the need for correction to protein and as soon
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24 hours post mortem. Furthermore, the donors were kept
cooled until harvest, but we cannot exclude that some
changes in composition might have occurred. However,
cartilage is not vascularised and remains very much un-
altered during the first 24 hours [55] and previous work
from our group showed no difference in viability between
freshly isolated chondrocytes from healthy, postmortem,
and grade III cartilage defect tissue [10].
Conclusions
Taken together, we showed that several proinflamma-
tory, proangiogenic and pro-repair cytokines were ele-
vated in patients with symptomatic cartilage defects and
OA, and that different cytokines were upregulated in
synovial fluid, cartilage tissue and isolated cartilage cells.
Research into the mechanisms governing this differential
release may shed light on the actual role of these factors
in degeneration and regeneration of cartilage tissue.
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